Lassen Therapeutics

Lassen Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California.

Founded in 2019, the company focuses on developing novel antibody biotherapeutics for serious diseases, particularly fibrotic, inflammatory, rare, and oncology-related conditions. Lassen is led by CEO Mark Barrett and Chief Scientific Officer David King, Ph.D., both experienced in antibody drug discovery. The company has raised $117 million in funding, including an oversubscribed $85 million Series B round completed in December 2023. Lassen Therapeutics is advancing its product pipeline with lead candidates such as LASN-01, a fully human monoclonal antibody targeting the IL-11 receptor, currently in a Phase 1 trial for Thyroid Eye Disease. Another candidate, LASN-500, is in early development for oncology applications. The company aims to address unmet medical needs in fibrotic diseases and cancer, leveraging advanced antibody technologies to improve patient outcomes.